Women’s health is not a niche – it is the next frontier for better medicine
For too long, women’s health has been treated as a specialist corner of healthcare rather than a central measure of whether our health systems, research priorities and innovation models are working as they should. That is beginning to change. The renewed Women’s Health Strategy for England, growing regulatory focus from the European Medicines Agency, and rising investment in FemTech all point to the same conclusion: women’s health is no longer peripheral. It is one of the most important frontiers for better medicine.
The case for change is compelling. Women represent around half of the global population, yet many conditions that predominantly or exclusively affect women have historically been underfunded, under-researched and underserved. Endometriosis, uterine fibroids, menopause-related symptoms, preeclampsia and other gynaecological and obstetric conditions continue to carry significant personal, social, and economic consequences. In many cases, the problem is not simply lack of treatment; it is a lack of understanding, lack of evidence and lack of urgency.
The gap matters because women can experience disease differently, respond to medicines differently, and move through healthcare pathways differently. If clinical research does not adequately reflect those realities, the evidence base is incomplete. If product development does not consider sex-specific biology and women’s lived experience, innovation risks missing the mark. And if investment continues to overlook women’s health, promising ideas will struggle to reach the patients who need them.
That is why the current momentum matters. The growth of FemTech and digital health is not just a consumer trend; it reflects a wider recognition that many women’s health needs have never been properly designed for. Digital therapeutics, remote monitoring, diagnostics, reproductive health technologies, menopause support, menstrual health tools and AI-enabled approaches all have the potential to improve access, earlier diagnosis and personalised care. But technology alone will not solve the problem. Innovation must be clinically robust, inclusive, evidence-based and built around needs rather than assumptions.
Regulators also have a critical role to play. The EMA’s focus on women’s representation in clinical trials, medicines assessment and labelling, pregnancy and breastfeeding evidence, and real-world data is a welcome signal that historical evidence gaps can no longer be accepted as inevitable. Earlier engagement with regulators could help developers address methodological challenges sooner and reduce uncertainty in areas where research has traditionally been limited.
The opportunity now is to move beyond awareness and into delivery. Women’s health needs sustained investment, stronger representation in research, more inclusive data, clearer development pathways and commercial confidence. It also needs collaboration between healthcare systems, regulators, investors, clinicians and patients.
If we get this right, the benefits will go far beyond individual products or services. Better women’s health research can improve medicines development. Better diagnostics can reduce years of avoidable suffering. Better digital tools can expand access and empower patients. Better evidence can improve outcomes for women.
Women’s health is not a niche. It is a test of whether modern healthcare is prepared to become more precise, more equitable and more effective for everyone.

Laurence Skillern
Chief Medical Officer
Meet the author
Laurence is responsible for leading Boyds’ clinical and medical service, supporting clients across the full drug development lifecycle, and strengthening the organization’s clinical and scientific capabilities. He has deep therapeutic expertise spanning women’s health, urology, rheumatology, neurodegenerative and metabolic diseases, as well as CNS and dermatological indications.